Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Translational Oncology|February 3, 2024
Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinomaMahlatse C M Kgokolo, Nonkululeko Z Malinga, Helen C Steel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 16, 2004
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an updateSteven M Grunberg, David Osoba, Paul J Hesketh, et al.
Frontiers in Pharmacology|October 22, 2021
Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in CancerBernardo L Rapoport, Vickie R Shannon, Tim Cooksley, et al.
BMC Cancer|September 29, 2020
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer typeCindy Weinstein, Karin Jordan, Stuart Green, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 30, 2018
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trialCindy Weinstein, Karin Jordan, Stuart A Green, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 2, 2009
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind studyBernardo L Rapoport, Karin Jordan, Judith A Boice, et al.
Cancers|January 21, 2023
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic ConsequencesMatteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, et al.
The Lancet. Oncology|August 15, 2015
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trialLee S Schwartzberg, Manuel R Modiano, Bernardo L Rapoport, et al.
Frontiers in Oncology|February 28, 2022
Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum PatientsMahlatse C M Kgokolo, Katherine Anderson, Shalate C Siwele, et al.
Translational Oncology|March 7, 2022
Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinomaNonkululeko Z Malinga, Shalete C Siwele, Helen C Steel, et al.
Pageof 6